

Reply

Dear Sora Yasri,

Thank you very much for your valuable comments and sharing your experience. We agree for your contribution. In thalassemia patients, several transplantation centers categorised risk factors prior to allogeneic hematopoietic stem cell transplantation. Pesaro classification assigned patients to three arms according to the absence or presence of one, two or three risk factors: hepatomegaly > 2 cm, portal fibrosis, and irregular chelation history [1]. It should be kept in mind that in a study by Ghavamzadeh et al., liver iron overload did not change after transplant ($p=0.61$) but hepatic fibrosis progressed ($p=0.01$) [2]. Allogeneic stem cell transplantation did not reduce liver iron overload and in fact liver fibrosis increased. Also steps for reducing iron overload should be taken in the post transplant setting [3]. Iron overload is still an essential issue in both pre

and post transplant settings. Survival in transfusion-dependent thalassemia patients can be improved with proper understanding of the pathophysiology of thalassemia and iron toxicity.

Regards,

Erden Atilla, Selami K. Toprak, Taner Demirer

References

1. Lucarelli G, Weatherall DJ. FFor debate: bone marrow transplantation for severe thalassaemia (1). The view from Pesaro (2). To be or not to be. Br J Haematol 1991;78:300-303.
2. Ghavamzadeh A, Mirzania M, Kamalian N, Sedighi N, Azimi P. Hepatic iron overload and fibrosis in patients with beta thalassemia major after hematopoietic stem cell transplantation: a pilot study. Int J Hematol Oncol Stem Cell Res 2015;9:55-59.
3. Bayanzay K, Alzoebe L. Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives. J Blood Med 2016;7:159-169.



Address for Correspondence/Yazışma Adresi: Sora YASRI, M.D.,
KMT Primary Care Center, Bangkok, Thailand
Phone: 6622578963
E-mail : sorayasri@outlook.co.th

Received/Geliş tarihi: December 23, 2016
Accepted/Kabul tarihi: December 26, 2016

DOI: 10.4274/tjh.2016.0493

Sole Infrequent Karyotypic Aberration Trisomy 6 in a Patient with Acute Myeloid Leukemia and Breast Cancer in Remission

Akut Miyeloid Lösemi ve Remisyonda Meme Kanserli Hastada Nadir İzole Karyotipik Bozukluk

Mürüvvet Seda Aydın¹, Süreyya Bozkurt², Gürsel Güneş¹, Ümit Yavuz Malkan¹, Tuncay Aslan¹, Sezgin Etgül¹, Yahya Büyükaşık¹, İbrahim Celalettin Haznedaroğlu¹, Nilgün Sayınalp¹, Hakan Göker¹, Haluk Demiroğlu¹, Osman İlhami Özcebe¹, Salih Aksu¹

¹Hacettepe University Faculty of Medicine, Department of Adult Hematology, Ankara, Turkey

²Hacettepe University Cancer Institute, Basic Oncology, Ankara, Turkey

To the Editor,

Cytogenetic abnormalities play important roles in the diagnosis and prognosis of leukemias [1]. Trisomy 6 as the sole karyotypic aberration is infrequent in leukemias [1,2]. A 50-year-old female patient presented with fatigue. She had been treated by mastectomy and given chemotherapy (no further information available) for breast cancer 3 years ago. She had been using tamoxifen for 3 years. Her breast cancer was in remission. Physical examination was consistent with a pale appearance. Hemoglobin, neutrophils, and platelet count were 8.5 g/dL, 900/ μ L, and 11,000/ μ L, respectively, on admission. In the peripheral blood smear, there were dysplastic features in monocytes and a few blasts were reported. In flow cytometry, CD13, CD33, CD34, CD45, CD117 (c-kit), HLA-DR, and MPO were positive. Bone marrow aspiration and biopsy revealed hypercellularity with

dysplastic and megaloblastic features in erythroid series, grade 1/3 reticulin fibrosis, and 24% blasts without ring sideroblasts, which in turn with cytometry findings were accepted as evidence of acute myeloid leukemia (AML). Bone marrow cytogenetic analysis revealed trisomy 6 (47,XX, +6 [20]) in all the metaphases (Figure 1). The patient was not in remission after the first induction treatment and she passed away due to septic shock during the second induction treatment.

Chromosome aberrations detected in therapy-related AML (t-AML) and de novo AML cases are identical but their frequencies may differ [3]. In a series at the University of Chicago, normal karyotypes were seen in 9.6% of t-AML cases [4]. In the report of Godley and Larson, among 306 patients with t-AML, 32 had solid breast cancer as the primary diagnosis [5]. Alkylating exposures and topoisomerase II inhibitors are associated with




Figure 1. Bone marrow cytogenetic analysis revealed trisomy 6 (47,XX,+6 [20]) in all the metaphases.

t-AML [3,6]. Godley and Larson mentioned granulocyte colony-stimulating factor usage as a risk factor in t-AML after breast cancer [5]. Unfortunately, we do not know which agents were given for our patient's breast cancer.

Autosomal trisomies have been described in several hematologic malignancy cases. The first case of sole trisomy 6 was reported in aplastic anemia. Other reports showed that trisomy 6 was associated with hypoplastic bone marrow, dyserythropoiesis, and AML [7]. Mohamed et al. reviewed 7 patients with trisomy 6. Patients presenting with overt AML had hyperplastic marrows [8]. Our patient had hypercellular marrow, as well. Mohamed et al. also reviewed the literature and found 4 MDS cases among 22 patients with trisomy 6 [8]. The marrow examination of this case revealed secondary dysplastic leukemia. The patient of Gupta et al. had de novo AML and did not respond to the first remission induction treatment [1].

Yu et al. reviewed ten reports in PubMed describing 18 cases of AML presenting with trisomy 6 as the sole karyotypic abnormality along with 3 cases of their own [7]. They concluded

that there were no direct correlations between the number of blasts and the percentage of abnormal metaphases. They could not identify any correlation between morphology or prognosis and trisomy 6 [7].

Under these circumstances, as in our case, we lack information on the impact of trisomy 6 on prognosis in secondary AML patients.

Keywords: Trisomy 6, acute myeloid leukemia, Breast cancer

Anahtar Sözcükler: Trizomi 6, Akut miyeloid lösemi, Meme kanseri

Conflict of Interest: The authors of this paper have no conflicts of interest, including specific financial interests, relationships, and/or affiliations relevant to the subject matter or materials included.

References

1. Gupta M, Radhakrishnan N, Mahapatra M, Saxena R. Trisomy chromosome 6 as a sole cytogenetic abnormality in acute myeloid leukemia. *Turk J Hematol* 2015;32:77-79.
2. Choi J, Song J, Kim SJ, Choi JR, Kim SJ, Min YH, Park TS, Cho SY, Kim MJ. Prognostic significance of trisomy 6 in an adult acute myeloid leukemia with t(8;21). *Cancer Genet Cytogenet* 2010;202:141-143.
3. Pedersen-Bjergaard J, Andersen MT, Andersen MK. Genetic pathways in the pathogenesis of therapy-related myelodysplasia and acute myeloid leukemia. *Hematology Am Soc Hematol Educ Program* 2007:392-397.
4. Qian Z, Joslin JM, Tennant TR, Reshmi SC, Young DJ, Stoddart A, Larson RA, Le Beau MM. Cytogenetic and genetic pathways in therapy-related acute myeloid leukemia. *Chem Biol Interact* 2010;184:50-57.
5. Godley LA, Larson RA. Therapy-related myeloid leukemia. *Semin Oncol* 2008;35:418-429.
6. Zhang L, Wang SA. A focused review of hematopoietic neoplasms occurring in the therapy-related setting. *Int J Clin Exp Pathol* 2014;7:3512-3523.
7. Yu S, Kwon MJ, Lee ST, Woo HY, Park H, Kim SH. Analysis of acute myeloid leukemia in Korean patients with sole trisomy 6. *Ann Lab Med* 2014;34:402-404.
8. Mohamed AN, Varterasian ML, Dobin SM, McConnell TS, Wolman SR, Rankin C, Willman CL, Head DR, Slovak ML. Trisomy 6 as a primary karyotypic aberration in hematologic disorders. *Cancer Genet Cytogenet* 1998;106:152-155.



Address for Correspondence/Yazışma Adresi: Mürüvvet Seda AYDIN, M.D.,
Hacettepe University Faculty of Medicine, Department of Adult Hematology, Ankara, Turkey

E-mail : muruvvetseda.balaban@hacettepe.edu.tr

Received/Geliş tarihi: January 17, 2016
Accepted/Kabul tarihi: November 15, 2016

DOI: 10.4274/tjh.2016.0030